Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G - Wikidata - wikimedia - TriplyDB

Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G

Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G

http://www.wikidata.org/entity/Q35063963

about

Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europe Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity.Anti-aβ oligomer IgG and surface sialic acid in intravenous immunoglobulin: measurement and correlation with clinical outcomes in Alzheimer's disease treatment.Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome.Differences in GlycA and lipoprotein particle parameters may help distinguish acute kawasaki disease from other febrile illnesses in children.Association of systemic lupus erythematosus with decreased immunosuppressive potential of the IgG glycome Fine specificities of natural regulatory T cells after IVIG therapy in patients with Kawasaki disease.The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease.Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients IVIG-mediated effector functions in autoimmune and inflammatory diseases.High-throughput analysis of immunoglobulin G glycosylation.10% liquid human immunoglobulin (KIOVIG(®)) for immunomodulation in autoimmune disorders.Biological roles of glycans.Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy.Antibody blood-brain barrier efflux is modulated by glycan modification.Treatment Options for Resistant Kawasaki Disease.Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?Sweet SIGNs: IgG glycosylation leads the way in IVIG-mediated resolution of inflammation.The prognostic role of abnormal liver function in IVIG unresponsiveness in Kawasaki disease: a meta-analysis.Role of sialylation in the anti-inflammatory activity of intravenous immunoglobulin - F(ab')₂ versus Fc sialylation

P2860

Q33419638-AE15968A-C367-4CD2-B4E2-43BFA3769169 Q33420853-953B19D8-6042-491A-80A0-C3C2DC506C9A Q35590968-B2642F22-D524-4492-BDCF-C2DFB5943B71 Q35670608-927014FF-DF06-49C8-98E9-F9C388699653 Q36123376-9B2D8613-C125-4DE8-95AE-242E527A164E Q36225198-E50F53AE-1C2B-4A70-A10D-11280329395E Q36669352-C3EE7319-E8C6-4CD7-835E-79EF2B2F66DF Q37175810-7DABB006-5121-46BA-8EA3-AB1DB82B0CB9 Q37732919-DB778346-DF27-4E2F-85A1-21E57400DE38 Q38699812-C99BB877-D796-483E-953B-2407067A35EF Q38797703-F34D215D-55E6-4593-A9F5-7022FC951759 Q38820352-F8E1440D-81DC-45DD-97D2-D73FB206FC67 Q38936714-B144C621-A0C7-408A-8A77-A4829C6E7CE1 Q39062945-342EF9FA-AE45-4321-8674-B8377121A8AA Q46348633-2578A94C-097F-469C-87E2-AEF85CD4404D Q47660588-68DDCA60-5D37-4F2D-87B8-D2A337F44A63 Q47804590-0D78BDF7-2F7D-47A9-8978-B368602BF25E Q50193260-012A8B35-9BF6-4833-8D4E-D796580C8179 Q53806066-A4533ED5-51DD-43FA-9BBE-D86DA2634249 Q57253408-AE8E2517-9FA8-407C-9C73-D65DC163F4D1

P2860

Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G

http://www.wikidata.org/entity/Q35063963

description

2013 nî lūn-bûn

@nan

2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Treatment response in Kawasaki ...... c intravenous immunoglobulin G

@ast

Treatment response in Kawasaki ...... c intravenous immunoglobulin G

@en

type

label

Treatment response in Kawasaki ...... c intravenous immunoglobulin G

@ast

Treatment response in Kawasaki ...... c intravenous immunoglobulin G

@en

prefLabel

Treatment response in Kawasaki ...... c intravenous immunoglobulin G

@ast

Treatment response in Kawasaki ...... c intravenous immunoglobulin G

@en

P1433

Q35063963-FD1550B8-8D89-4947-9516-F63248EA740F

P1476

Q35063963-D8BA97BE-445E-4225-AE1B-05FBDCD52F87

P2093

Q35063963-147C838D-531E-4FE3-8642-B523467DA9BA

Q35063963-20A40C50-0153-46C7-BDA0-8AB49F1ABC38

Q35063963-2A895A12-F958-4A9D-9A84-8C11460A7992

Q35063963-631A2F75-DB94-40A8-A5AB-E7679046F19F

Q35063963-91D0D303-2FFD-4658-88A9-B0FB0A9D4153

Q35063963-94FC9A10-EC13-4BBD-94AE-996EB69D49F3

Q35063963-979F6F55-3C29-4BC2-957B-2DCBF9C101E2

Q35063963-A36B663C-1A22-4697-8817-7C9BF8FE1A70

Q35063963-C570DECB-0922-4777-97D1-9969EB78A6AB

Q35063963-CB387CB0-A07F-4381-9D4A-8FA16297FCD6

P2860

Q35063963-025331B2-E042-4C87-B7A3-4CF205BCB742

Q35063963-02A887EC-C410-4D98-BDFC-8936A999AD47

Q35063963-030ECA62-FC1C-4D36-AAB2-0941FF62E6AA

Q35063963-0B8C9135-0001-4E26-8ADC-CD7971912687

Q35063963-0F88FEC6-2952-40EB-AB8A-66B3861F8AD9

Q35063963-0F96B284-2CD5-45D7-A994-D6F052196FFC

Q35063963-10BE2CAD-FF25-40BA-B137-115417E7F3A5

Q35063963-11238037-BB3E-49FF-A744-165FB650CDF2

Q35063963-134F42FE-BA4E-42B5-87D5-D49573CE26B1

Q35063963-140582A5-FA2F-4E34-98B5-D1F37A603FB0

P304

Q35063963-24B103F0-74B5-42C5-87EB-4DD6446871A1

P31

Q35063963-B3840ED2-ACF5-4FE0-BC16-9809F36F22D9

P356

Q35063963-77CF7864-050A-4398-A942-9F31556232B7

P407

Q35063963-2E16E593-3FEF-48B6-9CCD-F2AF077DAD38

P433

Q35063963-EDD483D1-067A-4B2C-AA3B-4A8B2C6BCD39

P478

Q35063963-53E004A3-8D80-47A3-BF3C-649DA38E3675

P50

Q35063963-A2469536-2FE7-4953-9047-B8E93C27A4C5

Q35063963-D5D21D47-3AF8-4753-82FC-EAB7B2515825

P577

Q35063963-EA1845A1-9981-4A81-88A6-EC26D537B184

P5875

Q35063963-218ABE7C-CE14-4A03-8424-C701EB67A75B

P698

Q35063963-0960B2F3-94CD-462E-926F-675149F3E309

P932

Q35063963-BFBF8451-4CB5-48F7-9039-801EAB0B874A

P356

JOURNAL.PONE.0081448

P1433

P1476

Treatment response in Kawasaki ...... c intravenous immunoglobulin G

@en

P2093

Adriana H Tremoulet

http://www.w3.org/2001/XMLSchema#string

Ajit Varki

http://www.w3.org/2001/XMLSchema#string

Alessandra Franco

http://www.w3.org/2001/XMLSchema#string

Biswa P Choudhury

http://www.w3.org/2001/XMLSchema#string

Jane C Burns

http://www.w3.org/2001/XMLSchema#string

John T Kanegaye

http://www.w3.org/2001/XMLSchema#string

Long T Hoang

http://www.w3.org/2001/XMLSchema#string

Natasha N Naidu

http://www.w3.org/2001/XMLSchema#string

Ranim Touma

http://www.w3.org/2001/XMLSchema#string

Shohei Ogata

http://www.w3.org/2001/XMLSchema#string

P2860

Chromosome mapping and organization of the human beta-galactoside alpha 2,6-sialyltransferase gene. Differential and cell-type specific usage of upstream exon sequences in B-lymphoblastoid cells

The structure of a human type III Fcgamma receptor in complex with Fc

Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity

Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1

Diagnosis, treatment, and long-term management of Kawasaki disease

A close look at human IgG sialylation and subclass distribution after lectin fractionation

Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharides

CD23/FcεRII: molecular multi-tasking

ST6Gal-I regulates macrophage apoptosis via α2-6 sialylation of the TNFR1 death receptor

Binding of human plasma sialoglycoproteins by the B cell-specific lectin CD22. Selective recognition of immunoglobulin M and haptoglobin

P304

e81448

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0081448

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Martin L. Hibberd

Chisato Shimizu

P577

2013-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259269114

http://www.w3.org/2001/XMLSchema#string

P698

24324693

http://www.w3.org/2001/XMLSchema#string

P932

3855660

http://www.w3.org/2001/XMLSchema#string